1. Operationalizing Value-Based Pricing of Medicines

   • Jon Sussex
   • Adrian Towse
   • Nancy Devlin

   Leading Article 07 November 2012 Pages: 1 - 10

   

2. Reference Pricing and Price Negotiations for Innovative New Drugs

   • Afschin Gandjour

   Commentary 06 November 2012 Pages: 11 - 14

3. Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma

   • Mary Kilonzo
   • Jenni Hislop
   • Luke Vale

   Review Article 05 December 2012 Pages: 15 - 24

4. A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice

   • Lotte Steuten
   • Gijs van de Wetering
   • Valesca Retèl

   Systematic Review 04 December 2012 Pages: 25 - 48

   

5. The Humanistic and Economic Burden of Systemic Lupus Erythematosus

   • Rachel Meacock
   • Nicola Dale
   • Mark J. Harrison

   Systematic Review 04 December 2012 Pages: 49 - 61

   

6. Cost Effectiveness of First-Line Oral Antiviral Therapies for Chronic Hepatitis B

   • María Buti
   • Itziar Oyagüez
   • Miguel A. Casado

   Systematic Review 05 December 2012 Pages: 63 - 75

   

7. Timely and Complete Publication of Economic Evaluations Alongside Randomized Controlled Trials

   • Joanna C. Thorn
   • Sian M. Noble
   • William Hollingworth

   Original Research Article 28 November 2012 Pages: 77 - 85

   

8. A Comment on Boyers et al.: “Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal”

   • Rachel Allen
   • Andres Brainsky
   • Tito Roccia

   Correspondence Open access 23 November 2012 Pages: 87 - 89

9. The Authors’ Reply to Allen et al.: “A Comment on Boyers et al.: ‘Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal’”

   • Dwayne Boyers
   • Xueli Jia
   • Graham Mowatt

   Correspondence 27 November 2012 Pages: 91 - 91